Thomas Neff, FibroGen
August 26, 2019 09:03 AM EDTUpdated 11:40 AM
R&D

Fi­bro­Gen founder and CEO Thomas Neff dies un­ex­pect­ed­ly as lead drug nears com­mer­cial thresh­old

John Carroll

Editor & Founder

Fi­bro­Gen founder and CEO Thomas Neff died “un­ex­pect­ed­ly” over the week­end, says the biotech com­pa­ny.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Bit­ter­root Bio nabs $145M Se­ries A with a plan to tack­le chal­leng­ing can­cer tar­get for heart med­i­cines

Up­dat­ed: FDA sig­nals like­ly full ap­proval for Ei­sai's new Alzheimer's drug ahead of Fri­day's ad­comm

Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

sponsored

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

A service from the Financial Times